duchenn
muscular
dystrophi
dmd
xlink
recess
condit
caus
mutat
huge
dystrophin
gene
common
seriou
form
childhood
muscl
wast
incid
live
male
birth
review
see
tissuespecif
control
least
seven
promot
fulllength
kda
dystrophin
isoform
encod
exon
span
mbp
express
primarili
skelet
cardiac
smooth
muscl
brain
review
see
love
et
preval
dmd
may
attribut
high
frequenc
de
novo
mutat
turn
influenc
size
natur
organ
dystrophin
gene
mani
dystrophin
intron
fivefold
eightfold
larger
averag
human
gene
kb
pair
one
three
case
dmd
present
prior
famili
fact
coupl
size
complex
gene
pose
great
challeng
prevent
genet
counsel
program
mutat
dystrophin
gene
identifi
caus
dmd
becam
appar
proteintrunc
defect
led
sever
form
muscl
wast
infram
delet
often
associ
milder
less
progress
form
muscl
wast
becker
muscular
dystrophi
bmd
dystrophin
gene
replac
therapi
becam
possibl
size
natur
widespread
express
skelet
muscl
soon
recogn
major
challeng
read
frame
hypothesi
propos
monaco
et
hold
true
major
case
although
except
explain
alter
gene
transcript
importantli
read
frame
rule
offer
two
potenti
avenu
therapi
insert
dystrophincod
sequenc
mildli
affectedasymptomat
bmd
patient
viral
vector
exploit
smaller
modifi
express
dystrophin
gene
remov
bypass
dmdcaus
mutat
function
bmdlike
dystrophin
isoform
produc
review
focu
novel
therapeut
compound
invok
avenu
intervent
either
restor
supplement
dystrophin
potenti
treatment
design
modul
muscl
patholog
dmd
tabl
strategi
offer
differ
target
intervent
may
complementari
therebi
provid
addit
possibl
therapeut
benefit
greatest
benefit
patient
like
deriv
dystrophin
restitut
howev
dmd
mutat
amen
molecular
intervent
individu
therapi
reduc
muscl
patholog
may
provid
least
interim
benefit
first
consid
potenti
treatment
design
modul
pathogen
process
aris
loss
function
dystrophin
isoform
discuss
nonvir
approach
directli
impact
upon
express
dystrophin
homologu
utrophin
corticosteroid
provid
best
treatment
option
avail
dmd
patient
date
also
use
limb
girdl
despit
signific
side
effect
somewhat
limit
therapeut
valu
drug
corticosteroid
stabil
muscl
short
term
advers
effect
common
clinic
use
corticosteroid
dmd
common
propos
gold
standard
treatment
may
despit
uncertainti
mode
action
benefit
steroid
dmd
short
term
valid
random
clinic
although
dosag
regimen
yet
standard
signific
impact
health
qualiti
life
health
care
cost
dmd
report
longterm
use
deflazacort
uncontrol
cohort
treat
boy
significantli
better
pulmonari
cardiac
function
remain
ambul
longer
untreat
combin
steroid
administr
respiratori
cardiac
manag
physic
care
led
dramat
improv
qualiti
life
mainten
function
longev
dmd
children
treat
multipl
intervent
possibl
life
expect
twice
born
optim
appropri
combin
indirect
treatment
restor
repair
replac
function
dystrophin
dramat
alter
natur
histori
dmd
justifi
steroid
common
use
probabl
muscular
dystrophi
patient
consid
subject
clinic
trial
investig
therapi
includ
molecular
intervent
take
treat
corticosteroid
imper
identifi
contraind
combin
treatment
also
identifi
agent
might
enhanc
effect
intervent
apart
corticosteroid
valid
therapi
dmd
avail
much
interest
nutrit
supplement
readytous
pharmacolog
agent
reduc
relentless
progress
diseas
avail
mdx
golden
retriev
muscular
dystrophi
grmd
dystrophinopathi
model
led
extens
preclin
studi
potenti
therapeut
howev
lack
standard
experiment
end
point
mdx
phenotyp
variat
dog
togeth
high
cost
maintain
dog
made
rigor
comparison
difficult
evalu
number
compound
abil
limit
declin
muscl
strength
mdx
mice
granchelli
et
indic
prednison
pentoxifyllin
insulinlik
growth
factor
glutamin
glutamin
plu
alanin
creatinin
improv
muscl
strength
subsequ
studi
fail
confirm
find
particularli
treatment
durat
extend
implement
valid
preclin
assess
mdx
includ
vivo
function
end
point
histopatholog
biochem
marker
facilit
rigor
comparison
preclin
data
differ
laboratori
expedit
evalu
mdx
mous
lead
effect
clinic
treatment
although
mdx
mous
appropri
molecular
dystrophinopathi
model
valid
clinic
model
dmd
mild
dystroph
patholog
muscl
diaphragm
debat
prompt
use
exercis
mdx
mice
show
typic
pattern
muscl
weak
vivo
exacerb
dystroph
patholog
conduct
chlorid
mdx
muscl
impair
chronic
exercis
respond
treatment
compound
stimul
regener
steroid
imped
calciuminduc
degener
inflamm
taurin
steroid
shortterm
benefici
effect
dystroph
patholog
mdx
mice
use
number
agent
includ
corticosteroid
arginin
report
chronic
continu
treatment
prednison
show
deleteri
effect
skelet
cardiac
arginin
lead
fibrosi
dystroph
heart
prednisolon
treatment
mdx
mice
affect
forc
loss
eccentr
contract
recoveri
forc
follow
injuri
data
emphas
limit
use
mice
preclin
model
dmd
increas
muscl
strength
boy
dmd
take
prednisolon
appear
occur
via
mechan
dystroph
payn
evalu
potenti
benefit
creatin
monohydr
conjug
linol
acid
alphalipo
acid
betahydroxybetamethylbutyr
alon
combin
prednisolon
exercis
mdx
mice
report
evid
therapeut
benefit
fourcompound
combin
therapi
alon
togeth
corticosteroid
evid
support
essenti
role
function
ischemia
contractioninduc
myofib
damag
twohit
mechan
mdx
mice
report
asai
et
vasoact
drug
tadalafil
phosphodiesteras
type
inhibitor
administ
mdx
mice
amelior
muscl
damag
prompt
studi
tadalafil
select
bmd
patient
tabl
skelet
muscl
mass
dynam
certain
environment
cue
condit
increas
differ
mechan
convers
reduc
activ
atrophi
pathway
induc
starvat
unload
diseas
henc
opportun
exist
intervent
muscular
dystrophi
promot
addit
new
myonuclei
grow
regener
myofib
upregul
protein
synthesi
pathway
suppress
inflammatori
atrophi
pathway
myostatin
growth
differenti
factor
identifi
major
neg
regul
skelet
muscl
mass
myostatinnul
anim
show
remark
increas
mass
muscl
myostatin
gener
inact
form
two
separ
proteolyt
cleavag
first
remov
ntermin
signal
peptid
cleav
propeptid
domain
produc
activ
form
protein
inhibit
myostatin
pathway
repres
promis
strategi
influenc
muscl
mass
improv
function
outcom
musclewast
condit
review
see
patel
follistatin
natur
antagonist
myostatin
member
transform
growth
factor
beta
superfamili
overexpress
follistatin
mous
muscl
lead
profound
increas
skelet
muscl
mass
review
see
rodinoklapac
et
rose
et
disrupt
myostatin
signal
pathway
express
follistatinrel
gene
flrg
gdfassoci
serum
myostatin
result
substanti
improv
muscl
function
increas
mass
normal
dystroph
myostatin
regul
muscl
growth
appar
member
superfamili
influenc
muscl
mass
activin
also
member
famili
structur
relat
myostatin
activin
myostatin
signal
activin
type
ii
receptor
actriia
actriib
activ
regul
follistatin
flrg
intracellular
receptorinteract
protein
novel
mechan
review
see
recombin
solubl
form
activin
receptor
compos
extracellular
domain
actriib
receptor
human
immunoglobulin
fc
preclin
studi
mdx
studi
normal
volunt
promis
prompt
develop
see
http
dmd
patient
recruit
clinic
studi
determin
safe
well
toler
children
establish
optim
dosag
regimen
respect
safeti
pharmacodynam
activ
see
http
lee
present
evid
suggest
activin
may
one
ligand
regul
follistatin
function
myostatin
limit
muscl
mass
contractioninduc
injuri
major
contribut
factor
pathophysiolog
muscular
dystrophi
therapi
attenu
effect
variant
mediat
growth
hormon
signal
function
regul
complex
tissu
specif
mechanogrowth
factor
mgf
altern
splice
variant
express
significantli
increas
muscl
bone
tendon
follow
damag
result
mechan
stimuli
brain
heart
follow
ischemia
mgf
shown
activ
satellit
cell
muscl
result
hypertrophi
regener
review
see
dai
et
patient
current
recruit
studi
determin
whether
therapi
improv
preserv
muscl
function
dmd
see
http
degrad
skelet
muscl
extracellular
matrix
inflamm
fibrosi
common
patholog
featur
dmd
although
underli
mechan
remain
poorli
understood
strategi
amelior
dystroph
patholog
consid
kumar
postul
sinc
express
variou
matrix
metalloproteinas
increas
dystroph
muscl
suppress
could
dampen
extent
muscl
pathogenesi
dystrophin
defici
mdx
mice
receiv
three
intraperiton
inject
per
week
period
batimastat
broadspectrum
peptid
inhibitor
matrix
metalloproteinas
compar
shamtreat
control
mdx
mice
found
reduc
necrosi
infiltr
macrophag
centronucl
fiber
express
embryon
myosin
heavi
chain
delet
gene
mdx
mice
significantli
improv
muscl
regener
patholog
function
reduc
muscl
injuri
inflamm
pharmacolog
inhibit
activ
also
amelior
skelet
muscl
pathogenesi
enhanc
myofib
regener
mdx
oxid
stress
particular
abnorm
product
reactiv
oxygen
speci
mitochondria
monoamin
oxidas
identifi
contribut
dystroph
thu
administr
antioxid
could
theori
benefici
pargylin
monoamin
oxygenas
inhibitor
reduc
reactiv
oxygen
speci
accumul
along
benefici
effect
dystroph
phenotyp
muscl
strength
mous
muscular
dystrophi
model
includ
mdx
idebenon
cardioprotect
improv
exercis
perform
mdx
evalu
dmd
friedreich
ataxia
patient
dorchi
demonstr
green
tea
polyphenol
blend
deriv
extract
could
protect
primari
mdx
muscl
cell
oxid
damag
induc
hydrogen
peroxid
scaveng
improv
glutathion
balanc
dmd
patient
develop
clinic
signific
cardiomyopathi
second
decad
life
current
effect
therapi
cardiomyopathi
dmd
improv
palli
care
manag
respiratori
function
extend
live
patient
strategi
restor
dystrophin
skelet
muscl
result
restitut
cardiac
dystrophin
express
like
exacerb
thu
urgent
need
address
emerg
heart
diseas
dmd
chronic
infus
membranes
poloxam
sever
affect
dystroph
dog
reduc
myocardi
fibrosi
prevent
left
ventricular
food
drug
administr
approv
shortterm
applic
human
potenti
halt
progress
dystroph
cardiomyopathi
although
small
molecul
may
abl
promot
muscl
growth
membran
stabil
protect
cell
oxid
stress
anoth
approach
reli
novel
compound
specif
upregul
express
homolog
gene
shortli
dystrophin
gene
identifi
love
identifi
autosom
gene
transcript
show
strong
homolog
dystrophin
utrophin
homologu
dystrophin
express
fetal
develop
restrict
neuromuscular
junction
matur
muscl
fiber
subsequ
shown
abl
replac
dystrophin
suffici
overexpress
truncat
utrophin
ubiquit
overexpress
utrophin
mdx
mous
prompt
search
compound
reactiv
utrophin
express
highthroughput
screen
identifi
sever
lead
compound
refin
valid
enter
singlecent
doubleblind
placebocontrol
singledos
escal
studi
follow
multipledos
escal
studi
healthi
volunt
sponsor
biomarin
howev
recent
announc
develop
bmn
biomarin
pharmaceut
inc
novato
ca
discontinu
due
pharmaceut
pharmacokinet
challeng
biomarin
conclud
approach
upregul
utrophin
may
feasibl
current
develop
addit
compound
take
forward
earli
human
studi
perhap
surpris
therapi
design
modul
one
downstream
pathogen
pathway
result
dystrophin
defici
confer
modest
transient
benefit
howev
approach
merit
glucocorticoid
confer
measur
transient
benefit
delay
declin
muscl
function
current
regard
standard
manag
dystrophin
play
pivot
role
form
stabil
link
actin
cytoskeleton
dystrophinassoci
complex
protein
embed
sarcolemma
consequ
restitut
dystrophin
degre
function
like
offer
tangibl
benefit
dmd
muscl
apart
dystrophin
express
mediat
gene
cell
therapi
two
distinct
strategi
overcom
dystrophin
mutat
shown
great
potenti
preclin
studi
decad
ago
particular
antibiot
aminoglycosid
famili
appear
promot
codon
misread
eukaryot
messeng
rna
mrna
translat
allow
readthrough
nonsens
mutat
review
see
use
gentamicin
one
first
compound
report
induc
readthrough
nonsens
mutat
provid
promis
data
appli
nonsens
mutat
cystic
fibrosi
transmembran
regul
essenti
codon
encod
amino
acid
normal
termin
codon
correctli
process
accumul
mistransl
protein
could
catastroph
discrimin
prematur
stop
codon
normal
stop
codon
consid
possibl
determin
context
surround
base
fourth
base
termin
codon
potenti
renal
otic
advers
effect
associ
gentamicin
exposur
well
document
prompt
search
compound
specif
induc
readthrough
nonsens
mutat
ataluren
ptc
therapeut
south
plainfield
nj
identifi
lead
compound
read
uga
termin
codon
compound
report
restor
dystrophin
express
human
mdx
mous
cell
carri
nonsens
mutat
dystrophin
gene
subsequ
experi
indic
substanti
express
induc
week
treatment
mdx
combin
intraperiton
oral
administr
regimen
prove
effect
promis
preclin
data
addit
phase
studi
healthi
volunt
doubleblind
placebocontrol
phase
iib
trial
initi
evalu
efficaci
safeti
period
particip
receiv
either
low
dose
ataluren
mgkgday
high
dose
mgkgday
placebo
despit
well
toler
particip
discontinu
treatment
due
advers
effect
primari
end
point
chang
walk
test
fail
reach
statist
signific
trial
ongo
studi
ataluren
dmd
patient
discontinu
time
addit
analysi
underway
patient
subgroup
whatev
final
outcom
studi
made
major
contribut
design
evalu
trial
dmd
therapi
set
import
efficaci
outcom
pivot
subsequ
dmd
studi
ataluren
evalu
continu
condit
includ
cystic
fibrosi
hemophilia
seem
appropri
consid
condit
may
benefit
modest
increas
target
protein
wherea
greater
express
dystrophin
necessari
physiolog
clinic
improv
mode
smallmolecul
screen
use
research
identifi
readthrough
compound
come
scrutini
auld
report
increas
firefli
luciferas
readout
posttransl
stabil
rather
readthrough
termin
codon
clearli
addit
studi
need
clarifi
issu
nonsens
mutat
readthrough
hold
great
promis
patient
afflict
wide
rang
inherit
disord
caus
nonsens
codon
mutat
paradox
despit
potenti
advers
side
effect
associ
longterm
gentamicin
administr
first
shortterm
gentamicin
studi
fail
detect
clinic
malik
recent
publish
data
openlabel
trial
unequivoc
demonstr
gentamicin
could
inde
restor
dystrophin
express
dmd
patient
carri
nonsens
mutat
two
cohort
receiv
daili
infus
gentamicin
mgkg
week
serum
creatin
kinas
reduc
cohort
dmd
individu
nonsens
mutat
wherea
chang
cohort
dmd
particip
whose
gene
inactiv
frameshift
delet
two
addit
cohort
receiv
low
dose
mgkg
either
weekli
biweekli
month
dystrophin
level
increas
highest
level
reach
normal
level
studi
appar
influenc
differ
prematur
stop
codon
sequenc
readthrough
effici
one
patient
appear
rais
antibodi
novel
dystrophin
protein
studi
justifi
highlight
need
continu
screen
compound
safe
induc
readthrough
prematur
termin
codon
studi
one
particip
cohort
receiv
biweekli
gentamicin
infus
inadvert
receiv
four
dose
intend
suffer
transient
highfrequ
hear
loss
withdrawn
studi
due
protocol
unequivoc
demonstr
dystrophin
restor
dmd
case
respons
gentamicin
treatment
prompt
resurg
interest
compound
effici
nonsens
mutat
readthrough
well
lower
toxic
profil
nudelman
report
vitro
studi
readthrough
sever
differ
mutat
use
aminoglycosid
subsequ
shown
far
less
toxic
gentamicin
dmd
therapeut
strategi
current
gain
consider
momentum
antisens
oligom
ao
induc
splice
manipul
dmdcaus
mutat
bypass
target
exon
remov
exon
skip
one
exon
flank
frameshift
exon
rearrang
may
remov
restor
read
frame
exon
carri
nonsens
mutat
mask
splice
machineri
remov
matur
gene
transcript
differ
mutat
across
dystrophin
gene
requir
specif
exonskip
strategi
necessit
potenti
score
oligom
unlik
experiment
therapi
evalu
upregul
homolog
readthrough
prematur
stop
review
see
nelson
et
exon
skip
must
regard
person
therapi
spread
differ
mutat
across
dystrophin
gene
requir
differ
exonskip
strategi
dmd
consid
orphan
diseas
base
criteria
affect
individu
usa
littl
incent
privat
sector
develop
market
specif
therapi
bring
drug
clinic
costli
challeng
orphan
diseas
statu
provid
incent
develop
treatment
rare
condit
howev
one
consid
score
differ
ao
would
need
treat
dmd
patient
differ
mutat
challeng
seem
insurmount
fundament
chang
drug
develop
pipelin
implement
exonskip
therapi
becom
realiti
amen
dmd
mutat
furri
interest
use
short
chemic
synthes
oligom
modifi
gene
express
zamecnik
describ
use
oligodeoxribonucleotid
odn
suppress
viral
replic
mani
subsequ
report
gene
suppress
eventu
attribut
nonsequencespecif
effect
often
relat
oligom
backbon
howev
new
gener
oligom
chemistri
develop
experiment
design
refin
becam
rigor
addit
methodolog
manipul
gene
express
use
ao
develop
includ
translat
suppress
gene
silenc
modif
premrna
splice
review
see
bennett
manipul
premrna
splice
alter
gene
express
downregul
transcript
induc
specif
isoform
suppress
abnorm
cryptic
splice
major
advantag
assess
chang
premrna
process
appear
novel
transcript
may
monitor
posit
assay
revers
transcriptas
polymeras
chain
reaction
rtpcr
detect
induc
protein
western
blot
gene
suppress
rnaseh
silenc
translat
blockad
problemat
assess
disappear
reduct
abund
transcript
protein
measur
neg
assay
absenc
evid
decreas
abund
gene
transcript
product
necessarili
irrefut
evid
absenc
offtarget
effect
oligom
may
compromis
global
transcript
translat
one
surpris
observ
high
proport
spliceswitch
ao
approxim
twothird
induc
degre
exon
approxim
onethird
spliceswitch
ao
initi
design
fail
induc
detect
effect
dystrophin
premrna
process
may
consid
unintent
neg
control
despit
complementari
dystrophin
premrna
appropri
design
spliceswitch
oligom
induc
specif
exon
skip
gener
novel
mrna
transcript
dosedepend
manner
loss
target
exon
bypass
proteintrunc
mutat
new
protein
gener
mind
omiss
earli
ao
design
seri
spliceswitch
oligom
control
includ
random
scrambl
unrel
sens
strand
sequenc
evalu
confirm
detect
chang
gene
express
sequenc
specif
attribut
oligom
chemistri
nonsequencespecif
howev
concept
exon
skip
well
establish
major
recent
report
dystrophin
splice
switch
includ
random
scrambl
sens
oligom
sequenc
neg
littl
doubt
target
exon
skip
assum
induc
adequ
effici
dystroph
muscl
would
reduc
sever
case
dmd
read
frame
rule
hold
true
major
dystrophin
discord
genotyp
phenotyp
normal
resolv
studi
dystrophin
mrna
identifi
secondari
effect
rna
process
consequ
ginjaar
identifi
nonsens
mutat
dystrophin
exon
one
bmd
famili
induc
differ
level
exon
skip
three
affect
boy
phenotyp
famili
vari
healthi
sever
affect
appear
correl
amount
exon
skip
sinc
loss
exon
disrupt
read
frame
remov
mutat
character
dystrophin
gene
structur
mildli
affect
asymptomat
bmd
individu
provid
templat
function
dystrophin
isoform
establish
region
protein
partial
furthermor
exon
skip
shown
occur
natur
evidenc
presenc
revert
dystrophinposit
fiber
mani
dmd
model
muscular
dystrophi
although
occur
frequenc
low
substanti
clinic
benefit
fiber
may
contribut
immun
toler
induc
bmdlike
dystrophin
success
implement
exon
skip
treat
dmd
requir
care
optim
oligom
design
evalu
deliveri
perhap
even
challeng
establish
product
develop
pipelin
bring
new
compound
clinic
applic
ao
induc
target
dystrophin
exon
skip
first
report
takeshima
detail
character
intraexon
delet
bp
dystrophin
exon
left
acceptor
donor
splice
site
intact
result
loss
entir
exon
seri
experi
use
differ
oligom
chemistri
vitro
assess
system
specif
remov
exon
induc
dystrophin
mrna
artifici
lymphoblastoid
later
human
mous
earli
spliceswitch
studi
mdx
mous
model
muscular
dystrophi
target
obviou
splice
site
intron
exon
acceptor
exon
intron
donor
splice
site
motif
offer
easili
defin
crucial
motif
involv
premrna
although
donor
splice
site
prove
amen
target
exon
skip
acceptor
site
unrespons
indic
limit
direct
ao
obviou
splice
design
ao
dystrophin
exon
chose
empir
approach
start
obviou
donor
acceptor
splice
site
intraexon
motif
potenti
exon
splice
enhanc
predict
bind
site
sr
protein
involv
exon
sever
hundr
ao
design
dystrophin
wilton
fletcher
unpublish
data
mechan
antisens
sequenc
influenc
exon
recognit
splice
still
clearli
defin
aartsmaru
suggest
intraexon
sequenc
provid
better
target
splice
site
propos
higher
gc
content
exon
offer
better
thermodynam
properti
author
conclud
design
ao
induc
exon
skip
dmd
target
exon
sequenc
like
result
effect
ao
howev
except
cours
optim
ao
often
requir
unlik
simpl
formula
set
thermodynam
paramet
guarante
design
effect
spliceswitch
ao
consider
variat
level
induc
exon
skip
within
exon
ao
length
target
sequenc
identifi
import
paramet
ao
wee
report
cotranscript
premrna
fold
influenc
aoinduc
dystrophin
exon
skip
secondari
structur
predict
frequenc
local
basepair
nucleotid
ao
target
site
correl
ao
perform
previous
report
compar
studi
sever
differ
ao
induc
human
dystrophin
exon
skip
target
donor
splice
site
prove
ineffect
despit
extens
microwalk
variat
ao
exon
difficult
remov
use
singl
ao
could
often
excis
select
ao
suggest
mani
factor
involv
exon
recognit
splice
clearli
oligom
prepar
induc
pronounc
exon
skip
cultur
cell
nm
effect
oligom
promot
weak
exon
remov
transfect
higher
clinic
applic
requir
ao
effect
low
dosag
thu
reduc
treatment
cost
likelihood
advers
effect
date
vitro
evalu
wide
use
select
ao
sequenc
dystrophin
exon
skip
recent
report
vitro
evalu
novel
ao
reflect
vivo
exonskip
activ
least
despit
strong
homolog
dystrophin
gene
human
mous
dog
direct
ao
premrna
motif
necessarili
induc
compar
exon
skip
although
mous
dystrophin
exon
readili
remov
target
donor
splice
site
human
equival
studi
compar
exon
human
mous
exon
skip
onethird
target
optim
speci
similarli
saito
report
motif
target
excis
canin
dystrophin
exon
also
effect
cell
dmd
patient
miss
exon
although
note
differ
remov
exon
two
speci
order
assess
ao
efficaci
import
accur
determin
chang
dystrophin
express
restor
induc
dystrophin
isoform
synthesi
ultim
amount
dystrophin
express
vivo
alter
progress
dmd
rather
experiment
enhanc
exon
skip
assess
rtpcr
previous
report
manipul
rtpcr
amplif
condit
exagger
appar
exon
skip
reflect
protein
increas
cycl
number
minim
length
amplicon
transcript
treat
mdx
sampl
appear
miss
target
exon
yet
dystrophin
detect
western
blot
seri
techniqu
quantifi
exon
skip
level
rtpcr
report
spitali
indic
quantif
small
primari
pcr
product
use
bioanalyz
densitometr
analysi
gener
data
close
digit
array
perhap
relev
assess
exon
skip
dystrophinisoform
restor
preclin
clinic
studi
quantif
protein
level
muscl
biopsi
base
upon
digit
captur
immunofluoresc
label
method
great
valu
allow
compar
quantif
sarcolemm
protein
allow
abund
local
protein
monitor
use
assess
experiment
therapi
partial
restor
protein
may
occur
effort
way
ensur
standard
test
order
data
differ
clinic
trial
differ
center
compar
directli
relev
exon
skip
also
therapi
design
supplement
compens
replac
dystrophin
sever
differ
oligom
chemistri
demonstr
capac
redirect
dystrophin
premrna
process
includ
dna
oligom
phosphorothio
backbon
odn
lock
nucleic
ethylen
nucleic
peptid
nucleic
rnalik
analog
base
phosphorothio
backbon
phosphorodiamid
morpholino
oligom
pmo
oligom
chemistri
specif
advantag
limit
date
three
differ
clinic
trial
report
use
odn
activ
recent
complet
clinic
trial
dmd
list
http
clinicaltrialsgov
summar
tabl
nucleic
acid
therapi
hamper
extent
limit
deliveri
distribut
case
dmd
complic
need
deliv
therapeut
level
oligom
skelet
total
bodi
mass
cardiac
smooth
muscl
tissu
ao
design
evalu
vitro
requir
transfect
either
high
concentr
compound
uptak
poor
use
deliveri
agent
enhanc
deliveri
larg
number
varieti
reagent
use
deliv
charg
ao
vitro
includ
cation
cation
uncharg
pmo
larg
ineffect
vitro
unless
appli
high
concentr
scrape
although
deliveri
greatli
enhanc
use
sens
strand
leash
cation
coupl
cellpenetr
peptid
cpp
octaguanidin
although
mani
deliveri
reagent
facilit
ao
uptak
vitro
applic
preclin
evalu
clinic
fortun
observ
uncomplex
pmo
effici
taken
dystroph
muscl
direct
intramuscular
inject
restor
robust
dystrophin
express
around
inject
exon
skip
appli
sever
anim
model
commonli
mdx
mous
carri
nonsens
mutat
exon
although
good
clinic
model
dmd
allow
numer
studi
assess
oligom
sequenc
modif
enhanc
pmo
deliveri
mous
model
studi
date
includ
mous
nonsens
mutat
exon
requir
remov
exon
mous
miss
exon
latter
anim
model
perhap
relev
origin
mdx
mous
model
sinc
mutat
occur
major
human
delet
hotspot
region
dystrophin
gene
human
contain
complet
copi
human
dmd
gene
integr
chromosom
promot
preclin
screen
humanspecif
oligom
comparison
differ
ao
sequenc
chemistri
mdx
mous
reflect
clinic
sever
dmd
human
mous
human
dystrophin
gene
process
rodent
splice
machineri
perhap
appropri
challeng
anim
model
test
exon
skip
therapi
dko
although
utrophin
dystrophin
null
anim
appear
normal
especi
earli
life
loss
gene
result
anim
sever
muscl
wast
dko
anim
typic
die
age
week
repeat
weekli
intraperiton
administr
pmo
conjug
cell
penetr
peptid
start
day
birth
found
prevent
onset
treat
anim
remain
normal
appear
year
age
goyenval
person
commun
demonstr
restor
bmdlike
dystrophin
isoform
model
highli
function
vivo
studi
use
grmd
canin
model
report
yokota
system
administr
substanti
amount
pmo
cocktail
excis
exon
restor
read
frame
around
exon
frameshift
work
particularli
encourag
larg
amount
pmo
administ
without
obviou
advers
effect
dystrophin
express
throughout
bodi
like
studi
use
similar
dosag
uncomplex
pmo
dystrophin
express
heart
low
undetect
presum
reflect
limit
uptak
howev
system
administr
singl
dose
uncomplex
pmo
gkg
result
dystrophin
restitut
skelet
cardiac
muscl
mdx
mous
without
clear
effici
ao
deliveri
mani
tissu
includ
heart
may
also
address
use
specif
cpp
coupl
research
recent
report
longterm
prevent
month
cardiac
dysfunct
earli
treatment
cpp
enhanc
pmo
deliveri
promis
activ
area
research
although
mani
cpp
examin
date
greatli
enhanc
pmo
uptak
concern
remain
regard
clinic
applic
compound
due
potenti
advers
effect
first
spliceswitch
clinic
trial
nonambul
dmd
patient
use
system
administr
odn
phosphorothio
backbon
design
excis
exon
restor
read
frame
around
dmdcaus
exon
although
dystrophin
exon
skip
demonstr
rna
extract
lymphocyt
infus
dystrophin
stain
equivoc
western
blot
data
present
inconclus
dystrophin
stain
n
studi
may
attribut
sever
factor
includ
readili
avail
lessthanoptim
oligom
chemistri
insuffici
dosag
durat
treatment
restor
detect
dystrophin
express
although
trial
gener
unequivoc
dystrophin
express
demonstr
benefit
recipi
advers
effect
compound
report
well
odn
typic
use
downregul
gene
express
induct
rnaseh
ubiquit
enzym
degrad
rna
strand
rna
odn
previous
demonstr
odn
induc
dystrophin
exon
vitro
transfect
much
higher
concentr
use
sequenc
prepar
ao
pmo
although
rnaseh
found
nucleu
ao
splice
switch
occur
cotranscript
process
presum
target
exon
excis
matur
mrna
transcript
would
longer
suscept
rnaseh
degrad
contrast
proofofconcept
studi
use
ao
pmo
chemistri
conclus
demonstr
induc
exon
skip
restor
dystrophin
read
frame
around
amen
dmd
delet
restor
dystrophin
express
local
deliveri
van
deutekom
report
administr
synthet
compos
modifi
base
phosphorothio
backbon
design
excis
exon
dystrophin
premrna
process
patient
delet
exon
inject
mg
tibiali
anterior
muscl
biopsi
taken
day
later
found
contain
high
proport
dystrophinposit
fiber
report
accur
quantif
skip
effici
meaning
correl
level
rna
protein
possibl
sinc
highsensit
rtpcr
condit
employ
nevertheless
result
suffici
encourag
proceed
system
administr
deliv
subcutan
weekli
dose
mgkg
sever
month
tantal
unpublish
data
report
indic
lowlevel
widespread
dystrophin
express
week
treatment
peerreview
publish
data
eagerli
await
propos
pmo
chemistri
better
suit
clinic
applic
induc
exon
skip
sustain
exon
skip
addit
pmo
develop
suppress
develop
number
clinic
trial
shown
excel
safeti
analysi
dmd
delet
frequenc
indic
exclus
exon
benefit
greatest
number
dmd
patient
exon
select
lead
target
exon
therapeut
exonskip
trial
compar
evalu
sever
pmo
sequenc
includ
one
select
preclin
compound
licens
univers
western
australia
avi
biopharma
bothel
wa
design
use
singleblind
placebocontrol
doseescal
studi
sponsor
mdex
consortium
confirm
proofofconcept
dmd
mutat
could
bypass
use
mdex
trial
structur
differ
studi
low
mg
high
mg
dose
administ
extensor
digitorum
brevi
one
foot
sham
salin
inject
appli
contralater
muscl
open
biopsi
muscl
perform
week
later
sampl
subject
rtpcr
immunohistochem
studi
clear
dose
respons
dystrophin
exon
skip
detect
muscl
receiv
low
dose
protein
evid
preestablish
test
condit
high
dose
exon
skip
readili
detect
rtpcr
test
biopsi
particip
unequivoc
dystrophin
express
determin
western
blot
immunofluoresc
preliminari
result
studi
suffici
encourag
commenc
doseescal
system
administr
dmd
particip
whose
genom
delet
would
read
frame
restor
exon
exclus
tabl
particip
divid
cohort
receiv
onceweekli
intraven
infus
dose
mgkg
muntoni
person
commun
data
indic
exon
skip
induc
dosedepend
manner
apart
one
individu
receiv
mgkg
found
strong
respond
particip
receiv
mgkg
transcript
miss
exon
protein
detect
boy
receiv
mgkg
show
strong
exon
skip
rtpcr
dystrophin
express
readili
detect
three
four
boy
cohort
one
boy
cohort
consider
higher
dystrophin
express
other
deem
strong
respond
summari
seven
patient
unequivoc
increas
dystrophin
express
compar
pre
posttreat
biopsi
muntoni
person
commun
extens
mdex
studi
offer
particip
stage
see
http
unfortun
consid
posit
outcom
term
dystrophin
express
higher
dose
one
attract
featur
pmo
chemistri
compound
appear
well
toler
pmorel
effect
cardiovascular
respiratori
global
neurolog
renal
liver
paramet
administr
maximum
feasibl
dose
mgkg
cynomolgu
mous
canin
model
muscular
dystrophi
receiv
differ
pmo
substanti
dosag
mgkg
grmd
gmkg
mdx
dystrophin
express
restor
without
overt
toxic
howev
consequ
longterm
exposur
dosag
yet
establish
furthermor
high
pmo
dose
may
offer
rapid
restitut
dystrophin
synthesi
unlik
even
high
dose
prove
safe
toler
amount
would
financi
sustain
time
recent
patent
protect
morpholino
synthesi
restrict
product
good
laboratori
practicecompli
pmo
product
facil
point
time
limit
potenti
manufactur
would
reluct
commit
major
capit
expenditur
expand
product
facil
especi
guarante
demand
although
pmo
exonskip
trial
gener
exceedingli
posit
data
obviou
clinic
benefit
yet
confer
particip
futur
requir
conpound
uncertain
time
nevertheless
pmo
product
technic
issu
involv
earli
molecular
biolog
experi
may
recal
high
cost
oligom
use
genespecif
probe
pcr
qualiti
reliabl
product
increas
also
cost
decreas
order
magnitud
respect
mani
similar
develop
penicillin
first
report
us
patient
treat
streptococc
septicemia
use
one
half
total
avail
suppli
produc
merck
co
whitehous
station
nj
time
penicillin
priceless
month
later
enough
materi
treat
patient
see
http
howev
respons
demand
treat
casualti
world
war
ii
concentr
effort
increas
product
cost
report
per
dose
treat
dmd
signific
longterm
benefit
confer
dystrophin
restitut
novel
experiment
therapi
treat
dmd
discuss
gentamicin
administr
oligomerinduc
exon
skip
result
readili
detect
dystrophin
express
dmd
patient
although
gentamicin
treatment
produc
promis
result
use
accompani
signific
side
effect
may
limit
longterm
administr
nonsens
mutat
readthrough
restrict
case
caus
prematur
termin
codon
potenti
applic
similar
percentag
wide
rang
inherit
disord
data
togeth
broad
applic
readthrough
compound
would
expect
acceler
develop
drug
search
compound
improv
safeti
profil
promis
clinic
data
dmd
exonskip
trial
anticip
drive
develop
field
particularli
rel
small
number
spliceswitch
compound
requir
treat
common
dmd
mutat
mani
compound
must
design
optim
address
amen
mutat
disadvantag
dmd
patient
ad
misfortun
rare
mutat
although
greatest
benefit
dystrophin
restitut
undoubtedli
deriv
earli
treatment
younger
patient
use
emerg
combin
therapi
aim
preserv
muscl
promot
muscl
repair
muscular
dystrophi
restor
protein
may
well
deliv
function
improv
older
patient
